the same negativities you point out in IMU also apply to RAC - you had a failed phase 2 in 2019 where only 10 patients were enrolled - it says the study was completed yet there were no results.... The Bisantrene combo therapy's were a failure in 2023 the results were littered with liver toxicity (10) and 5 patients out of 20 discontinuing due to death along with high infection rates. Your ever posting Director even said (on HotCopper mind you) they were deprioritising RC110 due to more value on RC220.
mate of this was all IMU results yourself and the other RAC band campers would be losing their mind.
If you're complaining about the exact same things from another company you have nothing to do with I suggest you take a step back and look at what you're invested in.
IMU Price at posting:
3.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)